Actinium Pharmaceuticals Inc (ATNM) - Total Assets
Based on the latest financial reports, Actinium Pharmaceuticals Inc (ATNM) holds total assets worth $45.44 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Actinium Pharmaceuticals Inc for net asset value and shareholders' equity analysis.
Actinium Pharmaceuticals Inc - Total Assets Trend (2006–2025)
This chart illustrates how Actinium Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Actinium Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Actinium Pharmaceuticals Inc's total assets of $45.44 Million consist of 95.4% current assets and 4.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Actinium Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Actinium Pharmaceuticals Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Actinium Pharmaceuticals Inc's current assets represent 95.4% of total assets in 2025, a decrease from 100.0% in 2006.
- Cash Position: Cash and equivalents constituted 92.7% of total assets in 2025, down from 100.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Actinium Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Actinium Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
USA | $107.75 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
China | CN¥3.42 Billion |
|
Bio-Thera Solutions Ltd
SHG:688177
|
China | CN¥2.39 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
Gubra A/S
CO:GUBRA
|
Denmark | Dkr1.32 Billion |
Actinium Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.89 | 9.35 | 21.47 |
| Quick Ratio | 5.89 | 9.35 | 21.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $35.91 Million | $59.35 Million | $79.30 Million |
Actinium Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Actinium Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.81 |
| Latest Market Cap to Assets Ratio | 0.72 |
| Asset Growth Rate (YoY) | -32.7% |
| Total Assets | $51.77 Million |
| Market Capitalization | $37.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Actinium Pharmaceuticals Inc's assets below their book value (0.72x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Actinium Pharmaceuticals Inc's assets decreased by 32.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Actinium Pharmaceuticals Inc (2006–2025)
The table below shows the annual total assets of Actinium Pharmaceuticals Inc from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $51.77 Million | -32.67% |
| 2024-12-31 | $76.90 Million | -5.58% |
| 2023-12-31 | $81.44 Million | -28.68% |
| 2022-12-31 | $114.19 Million | +42.05% |
| 2021-12-31 | $80.39 Million | +21.07% |
| 2020-12-31 | $66.40 Million | +468.93% |
| 2019-12-31 | $11.67 Million | -21.62% |
| 2018-12-31 | $14.89 Million | -18.80% |
| 2017-12-31 | $18.34 Million | -18.61% |
| 2016-12-31 | $22.53 Million | -15.27% |
| 2015-12-31 | $26.59 Million | +251.27% |
| 2014-12-31 | $7.57 Million | +31.28% |
| 2013-12-31 | $5.77 Million | -0.40% |
| 2012-12-31 | $5.79 Million | +3859114.67% |
| 2011-12-31 | $150.00 | 0.00% |
| 2010-12-31 | $150.00 | -92.93% |
| 2009-12-31 | $2.12K | -4.33% |
| 2008-12-31 | $2.22K | -65.52% |
| 2007-12-31 | $6.43K | +1280.47% |
| 2006-12-31 | $466.00 | -- |
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular… Read more